Abstract B38: Behavioral and clinical correlates of hepatocellular carcinoma among residents of South Central Texas: A case-control study

Le résumé fourni par la source

Abstract Latinos in South Texas (STX) are disproportionately diagnosed with Hepatocellular Carcinoma (HCC) compared to non-Hispanic whites (NHW) and Latinos in the U.S. The aims of this study were to characterize behavioral and clinical risk factors contributing to HCC incidence in our STX population. Methods: Controls and cases (104:51) were recruited from Bexar and 5 surrounding counties. Blood and urine samples were obtained from each subject and tested for liver function, Hepatitis B and C exposure, and blood/urine aflatoxin levels. Demographic and lifestyle data were obtained via questionnaire. Chi-squared and t-test analysis was utilized to determine bivariate case-control differences. Results: In bivariate analyses, HCC cases were older (57.3 vs. 49.7, p<0.001), and more likely to be male (OR = 8.44, p<0.001) or Latino (OR=2.17, p=0.045). HCC cases were also more likely to use alcohol (p<0.001) or smoke (p<0.001). They also were less likely to use aspirin (p=0.003) or statins (p=0.049) and less likely to engage in physical activity (p=0.038). Finally, HCC cases were more likely to have abnormal aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels (p< 0.001 for both), and higher levels of serum aflatoxin B1 (AFB1) (p=0.014). Conclusions: Findings confirm bivariate relationship between HCC incidence and risk factors in the general population. Citation Format: Amelie G. Ramirez, Edgar Muñoz, Dorothy Long-Parma, Alan E.C. Holden, Allen M. Treviño, Timothy D. Phillips, Bradley Pollock. Behavioral and clinical correlates of hepatocellular carcinoma among residents of South Central Texas: A case-control study. [abstract]. In: Proceedings of the Eighth AACR Conference on The Science of Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; Nov 13-16, 2015; Atlanta, GA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2016;25(3 Suppl):Abstract nr B38.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.